The University of Tennessee Research Foundation has selected Orion Therapeutics as the first recipient of its $5 million fund to support startups that bring research from the university’s labs to the market.
Orion is developing a new way to deliver drugs that use ribonucleic acid, or RNA, to new places in the body. RNA, the single-strand cousin of DNA, is increasingly used in medicines and vaccines to treat conditions ranging from muscular dystrophy to COVID-19.
Orion’s technology focuses on vascular diseases, such as dangerous buildup of plaque in arteries. It was founded in 2022 by a UT medical professor and her former graduate student.
Full story: News | Knoxville News Sentinel
